

# ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

**Invitation to**  
**11<sup>th</sup> Annual Course**

**“Anaemia, Neutropenia, Thrombocytopenia and Cancer”**

Hotel Barcelò Sants  
BARCELONA, SPAIN

**March 23<sup>rd</sup> - 24<sup>th</sup>, 2012**

**Chairs:**

C. Bokemeyer  
H. Ludwig  
P. Gascon

**Course co-ordinator:**

M. Apro

In collaboration with EORTC Anaemia Working Party and EORTC G-CSF Guidelines Working Party


CME accreditation via EACCME will be requested. This will be also AMA recognized.

Italian accreditation will be requested.

ESMO label will be requested.

A course made possible through educational grants from Amgen, J&J, Sandoz and Vifor


Support from other companies being requested



# ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

**Friday, March 23<sup>rd</sup>, 2012**


- 10:00**            **Registrations Open**
- 12:00-13:00**    Buffet Lunch
- 13:00-13:10**    **Welcome:** Chairmen and Coordinator
- 13:10-13:30**    **SESSION 1: Anaemia in Cancer Patients**  
Chairman: **H. Ludwig**
- 13:10-13:30    Pathophysiology and incidence of anaemia in cancer patient    **T. Littlewood**
- 13:35-14:50**    **SESSION 2: Neutropenia in Cancer Patients**  
Chairman: **M. Aapro**
- 13:35-13:50    EORTC guidelines for G-CSF usage. Any unsolved issues? Are they followed?    **M. Aapro**
- 13:55-14:10    Why do patients have pain with G-CSF    **P. Pronzato**
- 14:15-14:30    Models for FN risk assessment    **R. Pettengell**
- 14:35-14:50    What to do if FN hits: patient evaluation and empirical antibiotics    **J. Muñoz**
- 14:55-15:45**    **SESSION 3: Anaemia Management in Cancer Patients**  
Chairman: **M. Dicato**
- 14:55-15:15    Safety and efficacy of red blood cell transfusions    **A. Hofmann**
- 15:20-15:45    New avenues of research to fight anaemia? Which are the drugs on the horizon?    **J. Glaspy**
- 15:50-16:25**    **BREAK**
- 16:30-17:35**    **SESSION 4: Iron and Cancer Patients**  
Chairman: **H. Ludwig**
- 16:30-16:50    Pathophysiology of iron deficiency in cancer patients and the role of hepcidin    **Y. Béguin**
- 16:55-17:15    Iron deficiency in cancer patients: what to do in daily practice?    **H. Ludwig**
- 17:20-17:35    Are there concerns about iron use?    **A. Österborg**
- 17:40-19:15**    **SESSION 5: Thrombosis**  
Chairman: **M. Mandala**
- 17:40-18:00    Incidence and pathophysiology of thrombosis in cancer patients    **C. Ay**
- 18:05-18:25    LMWH: prophylaxis, therapy or survival: a critical review of the current evidence    **M. Mandala**
- 18:30-18:50    Anti-Xa in oncology (title subject to change)    **J. C. Reverter**
- 18:55-19:15    Title TBD    **G. Agnelli (TBC)**
- 19:20**            Closure of the day



# ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

**Saturday, March 24<sup>th</sup>, 2012**

- 09:00-09:25**    **SESSION 6: A debate about EPO: ESAs used per guidelines are safe**  
Chairman: **P. Gascon**
- 09:00            Vote from the floor
- 09:05-09:15    In favour  
**M. Apro**
- 09:15-09:25    Against  
**M. Dicato**
- 09:25            Vote from the floor
- 09:30-10:05**    **SESSION 7: Biosimilars: manufacturing and health cost implications**  
Chairman: **M. Dicato**
- 09:30-09:45    Process changes in manufacturing biologics and what is the position of the regulators?  
**H. Schellekens**
- 09:50-10:05    How to manage the rising cost in oncology? **P. Cornes**
- 10:10-10:40**    **BREAK**
- 10:45-11:50**    **SESSION 8: Anaemia beyond solid tumours**  
Chairman: **M. Apro**
- 10:45-11:10    Old and new studies in myeloma  
**H. Ludwig**
- 11:15-11:30    EPO in MDS  
**V. Santini**
- 11:35-11:50    Role of EPOs in lymphoma (Hodgkin's and non-Hodgkin's)  
**B. Coiffier**
- 11:55 -12:10    **CLOSING LECTURE**  
ITP treatment: possible relevance in oncology? Will we have a "thrombopoietin"?  
**M. Dicato**
- 12:15- 12:30**    **LEARNING ASSESSMENT (LA) FOR CME**
- 12:35**            **CME certificates given only to those participants who have completed the LA**
- 12:45-13:45**    Buffet Lunch



# ANAEMIA NEUTROPENIA THROMBOCYTOPENIA AND CANCER COURSE

## TOPICS COVERED DURING THE COURSE

### **Basic facts about anaemia, neutropenia and thrombocytopenia**

Short review of normal myelopoiesis  
Pathophysiology of anaemia in cancer  
Incidence of anaemia in cancer  
Importance of neutropenia in cancer  
Importance of thrombocytopenia in cancer

### **Symptoms and consequences of anaemia, neutropenia and thrombocytopenia**

Clinical symptoms – quality of life  
Consequences of anaemia on tumour progression and prognosis  
Consequences of neutropenia  
Consequences of thrombocytopenia

### **Treatment of anaemia and neutropenia in cancer patients**

Predicting risk of anaemia during chemotherapy  
Transfusions: pros and cons  
Erythropoietin and iron:

- Clinical results
- Impact on haemoglobin
- Impact on transfusion frequency
- Impact on quality of life
- Impact on outcome
- Prediction of response
- Economic aspects and biosimilars
- How to use them properly

Updated EORTC G-CSF use guidelines

### **Present and future developments**

Developments in immune thrombocytopenic purpura: any relevance for oncology?

### **Objectives of the Course**

This course should clarify issues related to anaemia and neutropenia in the cancer patient and the optimal way of preventing or treating these problems, including a review of EORTC guidelines for anaemia and neutropenia management. It will also focus on aspects still unresolved in the treatment of cancer treatment-associated anaemia like management of iron, discussed with participation from the audience. At the end of the course the participants should be able to better prescribe preventative or corrective actions in these areas for cancer patients and critically follow the development of this important field in the near future.